“Big data” and “open data”: What kind of access should researchers enjoy? - 09/03/16
participants of Giens XXXI, Round Table No. 6
pages | 8 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Summary |
The healthcare sector is currently facing a new paradigm, the explosion of “big data”. Coupled with advances in computer technology, the field of “big data” appears promising, allowing us to better understand the natural history of diseases, to follow-up new technologies (devices, drugs) implementation and to participate in precision medicine, etc. Data sources are multiple (medical and administrative data, electronic medical records, data from rapidly developing technologies such as DNA sequencing, connected devices, etc.) and heterogeneous while their use requires complex methods for accurate analysis. Moreover, faced with this new paradigm, we must determine who could (or should) have access to which data, how to combine collective interest and protection of personal data and how to finance in the long-term both operating costs and databases interrogation. This article analyses the opportunities and challenges related to the use of open and/or “big data”, from the viewpoint of pharmacologists and representatives of the pharmaceutical and medical device industry.
Le texte complet de cet article est disponible en PDF.Keywords : “Big data”, “Open data”, Anonymization, Connected objects, Data storage
Plan
☆ | Articles, analyses and proposals from the Giens workshops are those of the authors and do not prejudice the proposition of their parent organization. |
Vol 71 - N° 1
P. 107-114 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?